Perspective End Period Cash Flow from 2010 to 2024

CATX Stock   4.12  0.28  6.36%   
Perspective Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Perspective Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.28 and arithmetic mean of  15,820,989. View All Fundamentals
 
End Period Cash Flow  
First Reported
1998-12-31
Previous Quarter
252.2 M
Current Value
226.4 M
Quarterly Volatility
40.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Total Revenue of 1.4 M or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 55.63, Dividend Yield of 0.0 or PTB Ratio of 1.36. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Perspective Therapeutics Correlation against competitors.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Latest Perspective Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Perspective Therapeutics over the last few years. It is Perspective Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Perspective End Period Cash Flow Regression Statistics

Arithmetic Mean15,820,989
Geometric Mean6,601,005
Coefficient Of Variation142.05
Mean Deviation17,158,805
Median5,507,000
Standard Deviation22,473,277
Sample Variance505T
Range63.6M
R-Value0.53
Mean Square Error389.8T
R-Squared0.28
Significance0.04
Slope2,674,685
Total Sum of Squares7070.7T

Perspective End Period Cash Flow History

20249.9 M
20239.4 M
202156.1 M
202064 M
20192.6 M
20185.5 M
20172.6 M

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow9.4 M9.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.